Effect of the humanized monoclonal antibody against the interleukin-2 receptor alpha subunit (IL-2R-Alpha; Zenapax [daclizumab]) on inflammatory activity in the CNS [central nervous system] in MS [multiple sclerosis] in a baseline-to-treatment, cross-over, MRI [magnetic resonance imaging]-controlled single center phase I/II trial.

Trial Profile

Effect of the humanized monoclonal antibody against the interleukin-2 receptor alpha subunit (IL-2R-Alpha; Zenapax [daclizumab]) on inflammatory activity in the CNS [central nervous system] in MS [multiple sclerosis] in a baseline-to-treatment, cross-over, MRI [magnetic resonance imaging]-controlled single center phase I/II trial.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2011

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Dec 2008 Actual start date changed from 3 Sep 1999 to 1 Sep 1999 as reported by ClinicalTrials.gov.
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top